Evaluation of Rabies Biologics against Irkut Virus Isolated in China
Evaluation of Rabies Biologics against Irkut Virus Isolated in China
复制标题
中国分离的狂犬病生物制剂抗伊尔库特病毒的评价
DOI：
10.1128/jcm.01565-13
复制
发表时间：
2013-11-01
影响因子：
9.4
通讯作者：
Hu, Rongliang
中科院分区：
文献类型：
--
作者：
Liu, Ye;Chen, Qi;Hu, Rongliang
最近从中国的蝙蝠身上分离到一种伊尔库特病毒。通过暴露前预防(PrEP)和暴露后预防(PEP)实验，在仓鼠模型上评价了中国市场上的狂犬病生物制品和实验生物制品对狂犬病病毒(RABV)和狂犬病病毒(IRKV)的保护能力。结果表明，单剂狂犬病疫苗不能对IRKV感染产生足够的保护作用。然而，常规PrEP加三剂疫苗可对IRKV感染产生完全保护。在PEP过程中，需要更高剂量的RABV免疫球蛋白和α干扰素来保护仓鼠免受IRKV和RABV的感染。含有IRKV糖蛋白的实验重组疫苗对IRKV的保护作用比对RABV感染的保护作用更可靠。这些发现可以通过这些病毒的有限交叉中和(通过体外试验证实)以及RABV和IRKV之间的抗原距离来解释。这些结果表明，需要为PrEP和PEP开发和评估新的生物制品，以确保在中国和其他存在这种病毒的地区对IRKV感染有足够的保护。
An Irkut virus (IRKV) was recently isolated from a bat in China. The protective ability of rabies biologics available in the Chinese market and experimental biologics against the rabies virus (RABV) and IRKV were assessed in a hamster model via preexposure prophylaxis (PrEP) and postexposure prophylaxis (PEP) experiments. The results demonstrated that a single dose of rabies vaccine did not induce adequate protection against IRKV infection. However, routine PrEP with three doses of vaccine induced complete protection against IRKV infection. Higher doses of RABV immunoglobulins and alpha interferon were required during PEP to protect hamsters against IRKV versus RABV infection. Experimental recombinant vaccines containing IRKV glycoproteins induced more-reliable protection against IRKV than against RABV infection. Those findings may be explained by limited cross-neutralization of these viruses (confirmed via in vitro tests) in conjunction with antigenic distances between RABV and IRKV. These results indicate that the development and evaluation of new biologics for PrEP and PEP are required to ensure sufficient protection against IRKV infection in China and other territories where this virus is present.